Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Alberts, S. R.; Erlichman, C.; Sloan, J.; Okuno, S. H.; Burch, P. A.; Rubin, J.; Pitot, H. C.; Goldberg, R. M.; Adjei, A. A.; Atherton, P. J.; Kaufmann, S. H.; Annals of Oncology, 2001, vol. 12, issue 5, p 627, ISSN 09237534. ISBN 09237534.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef